tbuckley/cabot-search huggingface dataset:
Researchers Make Slow Progress In Establishing Prognostic Indicators for the Clinic
Authors: J. Bowersox
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article Researchers Make Slow Progress In Establishing Prognostic Indicators for the Clinic Get access John Bowersox John Bowersox Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 6, 17 March 1993, Pages 428–430, https://doi.org/10.1093/jnci/85.6.428 Published: 17 March 1993
SP0147 Using Cognitive-Behavioural Therapy to Help Patients Self-Manage Their Fatigue
Authors: S. Hewlett
Journal: Annals of the Rheumatic Diseases (2013)

<h3></h3> Fatigue is a common and severe problem for many patients with arthritis. It has a significant impact on all aspects of their lives, including not only doing daily tasks, but consequences on their relationships, family life and work. However, despite its frequency and severity (often worse than pain), research shows that patients feel that the rheumatology team does not offer support for managing fatigue and that they struggle to manage it alone. Further, research shows that nurses do not know what support to offer. A systematic review of trials, suggests some evidence for exercise interventions and for psycho-social interventions, including cognitive behavioural therapy (CBT). CBT is an approach that examines the links between thoughts, feelings and behaviours and how these may be influencing symptoms. For example, someone who continues to work overtime in the office, despite severe fatigue from arthritis, may be driven by thoughts that must always do everything perfectly, underpinned by feelings of anxiety that their colleagues will think less of them if they go home on time. Thus their behaviour and hence their fatigue, is partly driven by their thoughts and feelings, and they are unlikely to reduce their working hours just because a health professional tells them this is what they must do. People are best convinced by their own arguments, therefore the aim of CBT is to structure the discussion in such a way that the patient can work out the answers to the questions about their behaviour themselves (Socratic questioning). With help, patients can work out what thoughts and feelings drive their behaviours, and then they can be helped toward challenging those thoughts and feelings (and eventually the behaviours). In addition to Socratic questioning, CBT incorporates other techniques such as the use of daily diaries to help people understand their own behaviour patterns, trying experiments to make changes, helping people understand choices they are making and options available, and the use of peers to help them learn, as well as goal-setting (covered by another speaker). This presentation will examine how health care professionals might use a cognitive behavioural approach in their clinical practice when supporting patients with fatigue. It will provide useful tips that professionals might like to try out in clinic. The evidence-base will be from a published RCT of fatigue self-management. <h3>Disclosure of Interest</h3> None Declared
A comparison of cognitive impairment due to benzodiazepines and to narcotics
Authors: N Hendler, C Cimini, T Ma, D Long
Journal: American Journal of Psychiatry (1980)

In an attempt to determine the source of cognitive impairment in 106 consecutively admitted patients at the Johns Hopkins Chronic Pain Treatment Center, EEG, the Wechsler Adult Intelligence Scale, Memory Quotient, and Bender Gestalt tests were administered. Patients receiving benzodiazepines alone demonstrated alterations in cognitive functioning and EEG evidence of a sedative effect. Patients receiving narcotics alone and a group of patients not receiving medication did not show signs of cognitive impairment. The effects of benzodiazepines on sleep and perception of chronic pain, in combination with the cortical changes that they produce, imply that these drugs should not be used in most patients with chronic pain.
Technique for Temporary Pelvic Stabilization after Trauma
Authors: Taufiek K. Rajab, Michael J. Weaver, Joaquim M. Havens
Journal: New England Journal of Medicine (2013)

Early temporary pelvic stabilization can reduce hemorrhage from pelvic-ring fractures. This video demonstrates the use of pelvic sheeting to provide mechanical stabilization of pelvic-ring fracture.
PSOAS MUSCLE AREA PREDICTS POST-OPERATIVE MORTALITY IN OLDER ADULTS UNDERGOING ENDOVASCULAR OR OPEN AORTIC ANEURYSM REPAIR
Authors: Laura Drudi, Kim Phung, Matthew Ades, Jesse Zukerman, Louis Mullie, Kristoff Nelson, Samuel Mamane, Mark Levental, Cherrie Abraham, Daniel I. Obrand, Jonathan Afilalo
Journal: Journal of the American College of Cardiology (2016)
AB0105 The impact of inflammation on metabolomic profiles in patients with arthritis
Authors: S. R. Kapoor, A. Filer, C. Buckley, S. P. Young, K. Raza
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> In addition to synovitis, rheumatoid arthritis (RA) is characterised by widespread systemic changes. These changes are largely mediated by pro-inflammatory cytokines that impact on metabolism, particularly that of muscle and fat. Given these widespread metabolic effects we hypothesised that the level of current inflammation would be reflected in changes in the types and levels of metabolites found in the serum of patients with inflammatory arthritis. <h3>Objectives</h3> We have used NMR-based metabolomic fingerprinting to analyse serum from patients with newly presenting established RA, early arthritis and healthy controls. We sought to assess whether the metabolite fingerprint in patients with established RA differed from that of healthy controls and whether this fingerprint differed in patients with early arthritis in relation to the extent of inflammation and final outcomes. <h3>Methods</h3> Serum samples were collected from newly presenting, disease-modifying drug naive patients with established RA (16 patients), matched healthy controls (14 patients), and two groups of newly presenting patients with synovitis of ≤3 months’ symptom duration (89 patients and 127 patients) whose outcomes were determined at clinical follow-up. Serum metabolic profiles were assessed using 1D <sup>1</sup>H-NMR spectroscopy. Discriminating metabolites were identified, and the relationships between metabolic profiles and clinical variables including CRP and outcomes were examined. <h3>Results</h3> The serum metabolite fingerprint in established RA was clearly distinct from that of healthy controls. In early arthritis, we were able to stratify the patients according to the level of current inflammation, with CRP correlating with metabolic differences in two separate groups (p&lt;0.001). Lactate, glucose, cholesterol, fatty acids and lipids were important discriminators of inflammatory burden in both early arthritis patient groups. <h3>Conclusions</h3> The metabolomic fingerprint reflects inflammatory disease activity in patients with synovitis, demonstrating that underlying inflammatory processes drive widespread changes in metabolism that can be measured in the peripheral blood. The identification of novel metabolic alterations may provide insights into disease mechanisms operating in patients with inflammatory arthritis and provide novel variables that may add discriminating value to existing predictive algorithms. <h3>Disclosure of Interest</h3> None Declared
THU0235 Prevention of Development of Rheumatoid Arthritis (RA) in Patients with Undifferentiated Arthritis (UA) by Very Early Therapeutic Intervention of Methotrexate (MTX)
Authors: E. Kudo-Tanaka, M. Matsushita, S. Tsuji, M. Hirao, H. Tsuboi, Y. Katada, M. Sueishi, Y. Suenaga, J. Chiba, T. Tonai, K. Saisho, A. Ogata, J. Hashimoto, S. Ohshima, Y. Saeki
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Recent cumulative evidence suggests that early therapeutic intervention by DMARDs including MTX could prevent progression of RA. However, it is not clarified how early and which population of the patients should be taken early therapeutic intervention by DMARDs. Previously we reported that the patients with early-onset UA (EUA) showing high-titer anti-citrullinated peptide antibodies (ACPA) (&gt;15 U/ml) developed RA within a year at high-rate (&gt;80%) (ref.1). <h3>Objectives</h3> To examine whether very early therapeutic intervention of MTX could prevent development of RA in the patients with EUA showing high-titer of ACPA. <h3>Methods</h3> A prospective controlled study was conducted. The total number of 48 patients with UA showing high-titer of ACPA (&gt;15 U/ml) who have never treated with any non-biologic DMARDs or biologics. All patients were fulfilled with 1994 JCR classification criteria for early RA (ref.2) but not 1987 ACR classification for RA. They participated in this study with given written informed consents and divided into two groups according to their decision. One group was treated with MTX concomitant with corticosteroid (PSL&lt; 10mg/day) and/or NSAID (MTX+ Group, n=30). The other was treated without MTX (MTX- Group, n=18). Primary endpoint was development of RA defined by fulfilling 1987 ACR classification for RA at a time point of one year after the entry. Supplementally bone-progression was assessed by Heijdi-modified Sharp scores (H-S score). <h3>Results</h3> As shown in Figure 1(Kaplan-Meier), 5 of the 30 patients (16.7%) in the MTX+ Group developed RA compared with 14 of the 18 patients (77.8%) in the MTX- Group (HR 0.214 [95% CI 0.093-0.495], <i>p</i> &lt; 0.001). Although the mean interval changes from the baseline of H-S score per year showed no significant differences in the two groups (MTX+ versus MTX- : 2.0 (SD7.6) versus 2.9 (SD4.7), <i>p =</i> 0.312), the number of patients without obvious radiographical progression was relatively more in MTX+ (18 /23, 78.3%) compared to in MTX- (6 /11, 54.5%). In addition, there were no particular findings regarding to adverse events. <h3>Image/graph</h3> <h3>Conclusions</h3> Although short-term observation, very early therapeutic intervention of MTX might prevent development of RA in some populations of EUA. <h3>References</h3> Kudo-Tanaka E et al. Clin Rheumatol 2007.26:1627-33. Yamamoto S. Ryumachi 1994.34:1013-8. <h3>Disclosure of Interest</h3> None Declared
DETECTION AND LOCALIZATION OF MYOCARDIAL INFARCTION BY GATED TC-99M MIBI (RP-30) MYOCARDIAL PERFUSION STUDY.
Authors: Lynne Roy, Jamshid Maddahi, Robert Merz, Allan Lew, Brian Griffin, Prediman Shah, Daniel Berman
Journal: Clinical Nuclear Medicine (1987)

Roy, Lynne; Maddahi, Jamshid; Merz, Robert; Lew, Allan; Griffin, Brian; Shah, Prediman; Berman, Daniel Author Information
Gene Therapy Trial for Lung Cancer: Caught Between the RAC and a Hard Place
Authors: S. Jenks
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article Gene Therapy Trial for Lung Cancer: Caught Between the RAC and a Hard Place Get access Susan Jenks Susan Jenks Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 5, 2 March 1994, Pages 332–333, https://doi.org/10.1093/jnci/86.5.332 Published: 02 March 1994
Identification of Actionable Mutations in Specimens from Patients with Lung Cancer At Shizuoka Cancer Center
Authors: H. Kenmotsu, Y. Koh, M. Serizawa, M. Isaka, K. Mori, T. Takahashi, M. Endo, T. Nakajima, Y. Ohde, N. Yamamoto
Journal: Annals of Oncology (2013)
LONGITUDINAL CHANGES IN MULTIPLE BIOMARKERS ARE ASSOCIATED WITH CARDIOTOXICITY IN BREAST CANCER PATIENTS TREATED WITH DOXORUBICIN, TAXANES AND TRASTUZUMAB
Authors: Virginia Shalkey Hahn, Mary Putt, Heloisa Sawaya, James Januzzi, Igal A. Sebag, Juan Plana, Michael Picard, Robert Gerszten, Elkan Halpern, Irene Kuter, Randolph Martin, Joseph Carver, Marielle Scherrer-Crosbie, Bonnie Ky
Journal: Journal of the American College of Cardiology (2015)
A8.28 Reconstituted high density lipoprotein (RHDL) modulates TH1 and TH17 immune responses and pro-inflammatory cytokine production in a murine model of rheumatoid arthritis
Authors: I Tiniakou, V I Zannis, D Boumpas, P Verginis, D Kardassis
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background and Objectives</h3> High density lipoprotein (HDL) has a variety of functions which confer protection from cardiovascular and other human diseases. Increased cardiovascular risk is observed in humans with autoimmune disorders such as rheumatoid arthritis (RA), which is associated with either low levels or dysfunctional HDL. Recent evidence suggests a role of HDL in modulating both innate and adaptive immune responses. We sought to investigate the role of rHDL during the development of an autoimmune response in the antigen-induced arthritis (AIA) mouse model. <h3>Materials and Methods</h3> C57BL/6 mice were subcutaneously immunised with ovalbumin (OVA) in complete Freund's adjuvant (CFA) and the inguinal lymph nodes (LN) were excised 9 days after the antigenic challenge. The LN cells were cultured <i>in vitro</i> in the presence of varying concentrations of reconstituted HDL (rHDL) in the presence or absence of OVA and OVA-specific immune responses were measured. To assess the effect of HDL on dendritic cell activation and maturation, mouse bone marrow was cultured with GM-CSF to generate dendritic cells (BM-DCs), which were collected, cultured and treated with LPS in the presence or absence of rHDL. <h3>Results</h3> Presence of rHDL significantly inhibited the proliferation of OVA-primed LN cells in vitro, in a dose-dependent manner, as indicated by IL-2 measurement. Suppressed proliferation accompanied by reduced levels of IFN-γ and IL-17 in culture supernatants indicating that rHDL modulates the induction of Th1 and Th17 effector cells. Finally, rHDL-treated LPS-stimulated BM-DCs secreted significantly lower amounts of pro-inflammatory cytokines such as IL-6 and IL-8 whereas secretion of TNF-α was not affected. <h3>Conclusions</h3> rHDL exerts a direct immunomodulatory function on T cells <i>in vitro</i> by suppressing their proliferation and the induction of Th1 and Th17 effector cells. Furthermore, rHDL modulate the secretion of pro-inflammatory cytokines by DCs. Ongoing work is focused on the delineation of the mechanism involved in the rHDL-mediated suppression of the immune response both <i>in vitro</i> and <i>in vivo.</i> These data identify rHDL as an important player in the homeostatic regulation of the inflammatory response and a potential therapeutic target for chronic inflammatory diseases.
CARDIOVASCULAR OUTCOMES IN A LARGE PROSPECTIVELY FOLLOWED SINGLE-CENTER COHORT OF SPONTANEOUS CORONARY ARTERY DISSECTION PATIENTS
Authors: Jacqueline W.L. Saw, Roshan Prakash, Andrew Starovoytov, Eve Aymong, Tara Sedlak, G.B. John Mancini
Journal: Journal of the American College of Cardiology (2016)
Tc-99m MAA Findings in Dilated Cardiomyopathy With Partial Anomalous Venous Connections
Authors: Shirou Ishii, Fumio Shishido, Masayuki Miyajima, Koutarou Sakuma, Takeshi Shigihara, Ken Kikuchi
Journal: Clinical Nuclear Medicine (2011)

Tc-99m MAA showed asymmetric uptake in the lung field in a 21-year-old man with dilated cardiomyopathy. CT revealed partial anomalous venous connections in the left upper lobe. Angiogram of the left pulmonary upper lobe showed all the contrast material drained into the left vertical vein. The possible cause of relative increase in the left upper lobe blood flow is that right pulmonary blood flow is slowed by the high pressure in the left atrium due to dilated cardiomyopathy, whereas the flow from the left upper lobe drains into the superior vena cava which has less pressure than left atrium.
268 SAFETY AND TOXICITY OF THE COMBINATION OF Y90-RADIOEMBOLIZATION AND SORAFENIB IN ADVANCED HCC: AN INTERIM ANALYSIS OF THE EUROPEAN MULTICENTER TRIAL SORAMIC
Authors: J. Ricke, K. Bulla, J. Walecki, E. Schott, B. Sangro, F. Kolligs, H. Amthauer, C. Verslype, P. Reimer, K. Schütte, M. Peck- Radosaljevic, P. Malfertheiner
Journal: Journal of Hepatology (2013)
Primary Hyperparathyroidism Associated with Hypomagnesemia
Authors: James W. Agna, Richard E. Goldsmith
Journal: New England Journal of Medicine (1958)

CONCLUSIVE evidence of a clinical syndrome related to a deficiency of magnesium in man is lacking. We have had the opportunity recently to observe 3 patients who, in the course of adenomatous hyperparathyroidism proved by surgical exploration, demonstrated clinical abnormalities believed to be related to magnesium deficiency. A preliminary report has been published.1 MethodsThe serum and urine magnesium concentrations of Cases 1 and 3 were determined by the method of Briggs.2 With duplicate aliquots of serum and urine, calcium was precipitated as calcium oxalate, and from aliquots of the supernatant magnesium was precipitated as magnesium ammonium phosphate. A slight . . .
Abstract 348: Prognostic value of mTOR activation and therapeutic effects of everolimus in esophageal squamous cell carcinoma
Authors: Kotaro Hirashima, Yoshifumi Baba, Seiya Saito, Kouichi Kinoshita, Nobutaka Satou, Junji Kurashige, Ryu-ichi Karashima, Yu Imamura, Osamu Ikeda, Naoko Hayashi, Masayuki Watanabe, Ken-ichi Iyama, Hideo Baba
Journal: Cancer Research (2010)

Abstract Background: The mammalian target of rapamycin (mTOR) plays central roles in cell growth and homeostasis. Aberrant activation of mTOR in relation to clinical outcome has been reported in several types of cancers. mTOR inhibitor, particularly everolimus (RAD001), has been attracting attentions as a promising anticancer drug. Nonetheless, no study has shown the prognostic value of mTOR activation in oesophageal squamous cell carcinoma (ESCC) and the therapeutic effect of everolimus on human ESCC cell lines. The aims of this study are [1] to evaluate phosphorylated-mTOR (i.e., mTOR activation) expression in ESCC and to clarify its clinical, pathologic, and prognostic features and [2] to examine the therapeutic effect of everolimus on ESCC cell lines. Methods: We examined p-mTOR expression (i.e., mTOR activation) by immunohistochemistry using 143 ESCC specimens. The present study involved 143 consecutive patients with ESCC who underwent the curative surgical resection at Kumamoto University Hospital from January 1996 to December 2006. We determined its clinical, pathologic, and prognostic features. Prognostic significance of p-mTOR expression was examined by Cox regression and Kaplan-Meier analysis. Subsequently. the effects of everolimus on ESCC cell lines were evaluated by in vitro assays (proliferation, cell cycle, apoptosis, invasion). Results: p-mTOR expression was detected in 71 (49.7 %) tumors and was independently associated with higher overall mortality. Compared to p-mTOR negative patients, p-mTOR positive patients experienced high overall mortality [HR 2.44; 95% confidence interval (CI), 1.24-4.83, P = 0.01], which persisted in multivariate analysis (adjusted HR 2.92; 95% CI, 1.48-5.78, P = 0.002). p-mTOR expression was not related with clinical or pathologic variables including age at diagnosis, sex, tumor location, histological grading, T classification (tumor invasion) or N classification (lymph-node metastasis). In vitro, in both TE4 (p-mTOR expression-high in vitro) and TE11 (p-mTOR expression-low in vitro) squamous cell carcinoma cell lines, everolimus suppressed the phosphorylation of downstream p70S6 kinase and 4E-BP1in a dose-dependent manner. Everolimus significantly inhibited cancer cells proliferation and invasion, and induced cells apoptosis in vitro. Conclusion: p-mTOR expression in ESCC was independently associated with poor prognosis, supporting the potential for mTOR as a therapeutic target for ESCC. Everolimus may be useful as an anticancer drug for ESCC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 348.
Scarring mucous membrane pemphigoid presenting as double stenosis of the larynx and esophagus: precautions during therapy can avoid complications
Authors: Ulrike Schempf, Ruben Plentz, Dietmar Stueker, Martin Goetz, Hans Boesmueller, Beate Wietek, Thomas Kratt
Journal: Endoscopy (2014)

Mucous membrane pemphigoid (MMP) is a chronic immune bullous disease involving predominantly the mucous membranes. It is characterized by the formation of autoantibodies against components of the dermal–epidermal junction. The incidence of aerodigestive involvement is approximately 5 % to 15 % [1] [2] [3].
Abstract 4992: A novel role of soluble E-selectin as a chemoatractant to human leukocytes through the PI3kinase signaling pathway in breast cancer.
Authors: Celine A. Blache, Nafis Hasan, Jeehna Park, Stephen Suh, David G. Gorenstein, Hallgeir Rui, Takemi Tanaka
Journal: Cancer Research (2013)

Abstract Solid tumors are multicellular complexes where the tumor stroma that is comprised of endothelial cells, pericytes, fibroblasts and immune cells, all of which orchestrate to assist in cancer cell growth, angiogenesis and invasion. The tissue infiltration of immune cells is mediated by a multistep adhesion cascade and involves the selectin family of calcium-dependent cell surface glycoproteins Among this family, E-selectin (CD62E, ELAM-1 or LECAM-2) is exclusively expressed on the surface of endothelial cells in a highly inducible manner in response to inflammatory cytokines, and consequently an elevated E-selectin expression has been reported in many types of diseases including cancer. Endothelial E-selectin (eE-sel) assists in the initial adhesion of circulatory leukocytes to the surface of vascular endothelium by interacting with its ligands (sLeX, sLeA and CD44). The external domain of E-selectin can be cleaved off and shed into the circulation as soluble E-selectin (sE-sel). sE-sel is present in the serum of cancer patients and is associated with occurrence of metastases and poor survival in breast and colorectal cancers. However, the biological relevance of sE-sel is not clearly understood. In this study, we aim to identify the biological role of sE-sel in breast cancer growth. We have demonstrated that sE-sel enhances the adhesion and tissue migration of leukocytes into breast tumor both in vitro through the activation of PI3 kinase and its downstream signaling cascade. We have also demonstrated that 7 times more peripheral blood mononuclear cells (PBMC) migrate into breast tumor when pre-incubated with sE-sel as compared to untreated condition. Therefore, we conclude that sE-sel serves as a chemoattractant that enhances the tissue migration of leukocytes, which lead to the development of solid tumor stroma that enhances the growth of breast tumor and invasion. Citation Format: Celine A. Blache, Nafis Hasan, Jeehna Park, Stephen Suh, David G. Gorenstein, Hallgeir Rui, Takemi Tanaka. A novel role of soluble E-selectin as a chemoatractant to human leukocytes through the PI3kinase signaling pathway in breast cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4992. doi:10.1158/1538-7445.AM2013-4992